[ Back to EurekAlert! ] Public release date: 10-Jan-2006
[ | E-mail Article ]

Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory

Oncogenic role for Bcl-3

In an upcoming G&D paper, Dr. Albert Baldwin and colleagues (UNC School of Medicine) lend new insight into an alternate mechanism of p53 inactivation in tumor cells. The researchers found that the putative oncoprotein Bcl-3, which is expressed in some leukemias and solid tumors, potently suppresses p53 activation through a mechanism that involves the controlled upregulation of Hdm2 gene expression.

Additionally, they found that Bcl-3 is activated by DNA damage and is required for p53 to control Hdm2 gene expression. Thus the normal function of Bcl-3 appears to be to limit p53 activation and to suppress apoptosis. Constitutive expression of Bcl-3 in cancer, therefore, subverts the normal regulation of the p53 tumor suppressor mechanism leading to oncogenic potential.

###


[ Back to EurekAlert! ] [ | E-mail Article ]